Idiopathic Thrombocytopenic Purpura Therapeutics Market

Idiopathic Thrombocytopenic Purpura Therapeutics Market by Products (TPO-RA, Intravenous Immunoglobulin, Corticosteroids, Anti-D Immunoglobulin, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2503
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 218
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global idiopathic thrombocytopenic purpura therapeutics market size is estimated to register a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the presence of favorable government initiatives and regulations.

Idiopathic Thrombocytopenic Purpura Therapeutics Market

Idiopathic thrombocytopenic purpura (ITP) is a condition of low levels of platelets in the body due to excessive bleeding. The U.S. Food and Drug Administration (FDA) has declared that the disease have incidence rate of 3.3 cases per 100,000 in the country. As per the reports of European Medicines Agency, in Europe, the incidence rate is from 1.6 to 3.9 cases per 100,000 per year. One of the key aspects of the ITP therapeutics market is the presence of favorable government regulations and initiatives across several countries. For instance, the Orphan Drug Regulation, Japan, and Orphan Drug Act, the U.S. are two regulations that have several potential for commercialization of new drugs, which is expected to positively influence the market. Avatrombopag has resulted in positive clinical trial and is expected to provide patients with an alternative second line of treatment.

As per several reports related to clinical trials, the combination therapies have relatively lower side effects and are cost-effective besides having a higher positive response from patients. Some of the common combination therapies include rituximab and dexamethasone, corticosteroids and IVIG, and dexamethasone. Splenectomy and TPO-RA play an important role in shaping the dynamics of the ITP therapeutics market. The method is a removal of spleen and is focused at decreasing the amount of anti-platelet antibodies.

Market Trends, Drivers, Restraints, and Opportunities

  • High occurrence of road accidents and extreme activities that often result to cause excessive bleeding is expected to propel the market growth in the coming years.
  • Wide commercialization of innovative products related to the treatment of the disorder is expected to boost the market growth during the forecast period.
  • Development of innovative therapy technique especially in the combination therapies is expected to accelerate the growth of the market in the coming years.
  • Increasing R&D activities globally and healthcare expenditure is expected to offer lucrative opportunities for fueling the market growth in the long run.

Scope of the Report

The report on the global idiopathic thrombocytopenic purpura therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Idiopathic Thrombocytopenic Purpura Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (TPO-RA, Intravenous Immunoglobulin, Corticosteroids, Anti-D Immunoglobulin, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

F. Hoffmann-La Roche AG; Amgen Inc.; Grifols Biologicals Inc.; and GlaxoSmithKline Plc.

Market Segment Insights

Corticosteroids segment is expected to grow at a robust pace

Based on products, the global idiopathic thrombocytopenic purpura therapeutics market is divided into TPO-RA, intravenous immunoglobulin, corticosteroids, anti-d immunoglobulin, and others. The corticosteroids segment accounted for a key share of the market in 2019 and is expected to grow at a robust pace during the projected period as these are frequently used as the first line of therapy in patients. Meanwhile, the TPO-RA segment is anticipated to exhibit a high CAGR during the forecast period owing to high adoption rates by patients.

Idiopathic Thrombocytopenic Purpura Therapeutics Market

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to increasing incidence rates, presence of high treatment rates, funding programs, and favorable government initiatives in the region. The market of Asia Pacific, on the other hand, is anticipated to grow at a significant growth rate during the forecast period due to large presence of untapped opportunities in the region.

Idiopathic Thrombocytopenic Purpura Therapeutics Market

Segments

Segments Covered in the Report

The global idiopathic thrombocytopenic purpura therapeutics market has been segmented on the basis of

Products

  • TPO-RA
  • Intravenous Immunoglobulin
  • Corticosteroids
  • Anti-D Immunoglobulin
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • F. Hoffmann-La Roche AG
  • Amgen Inc.
  • Grifols Biologicals Inc.
  • GlaxoSmithKline Plc.

Competitive Landscape

Key players competing in the global idiopathic thrombocytopenic purpura therapeutics market are F. Hoffmann-La Roche AG; Amgen Inc.; Grifols Biologicals Inc.; and GlaxoSmithKline Plc. The main market players are continuously engaged in various business operational activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their consumer base globally.

Idiopathic Thrombocytopenic Purpura Therapeutics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market - Supply Chain
  4.5. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast
     4.5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Absolute $ Opportunity
5. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
6. North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
8. Europe Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Idiopathic Thrombocytopenic Purpura Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Idiopathic Thrombocytopenic Purpura Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Idiopathic Thrombocytopenic Purpura Therapeutics Market: Market Share Analysis
  11.2. Idiopathic Thrombocytopenic Purpura Therapeutics Distributors and Customers
  11.3. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report

The global idiopathic thrombocytopenic purpura therapeutics market has been segmented on the basis of

Products

  • TPO-RA
  • Intravenous Immunoglobulin
  • Corticosteroids
  • Anti-D Immunoglobulin
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • F. Hoffmann-La Roche AG
  • Amgen Inc.
  • Grifols Biologicals Inc.
  • GlaxoSmithKline Plc.

Key players competing in the global idiopathic thrombocytopenic purpura therapeutics market are F. Hoffmann-La Roche AG; Amgen Inc.; Grifols Biologicals Inc.; and GlaxoSmithKline Plc. The main market players are continuously engaged in various business operational activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their consumer base globally.

Idiopathic Thrombocytopenic Purpura Therapeutics Market

Buy Report